Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06351761 · ClinicalTrials.gov registry record · NA

WIBOFA - Validation of SCT02 With ECG-App for Detection of AF

A NA study of Atrial Fibrillation, sponsored by Withings.

Completed
Registry status
NA
Development phase
373
Enrollment target
4
Study locations

NCT06351761 is a NA study of Atrial Fibrillation that has completed, run by Withings. The registered enrollment target is 373 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06351761, a NA study of Atrial Fibrillation, has completed, sponsored by Withings.

COMPLETED
Registry status
NA
Development phase
373 participants
Enrollment target
4
Study locations

Study Summary

The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

Conditions Studied

Interventions

  • DEVICE Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
  • DEVICE Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording

Study Locations (4)

Florida

  • FWD Clinical Research - Boca Raton
  • Diverse Clinical Research - Miami

Val de Marne

  • Henri Mondor University Hospital - Créteil

Other

  • Centre Cardiopole Trubert - Paris

Trial Details

FieldValue
Enrollment Target 373 participants
Start Date 2024-06-03
Est. Completion 2025-11-26
Phase NA

Sponsor

Withings

5 total trials

What the Registry Record Tells You About NCT06351761

The ClinicalTrials.gov registry entry for NCT06351761 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The listed sponsor is Withings, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Investigational Device (Withings SCT02) 30 second Electrocardiogram recording is the first listed.

NCT06351761 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Val de Marne, Other.

Frequently Asked Questions

What is clinical trial NCT06351761 about?

NCT06351761 is a clinical study titled "WIBOFA - Validation of SCT02 With ECG-App for Detection of AF". The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

What is the current status of trial NCT06351761?

This trial is currently completed. It is a NA study. The enrollment target is 373 participants. The study started on 2024-06-03. Estimated completion is 2025-11-26.

What conditions does trial NCT06351761 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT06351761?

The interventions under investigation include: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording (DEVICE), Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording (DEVICE).

Who is sponsoring clinical trial NCT06351761?

This trial is sponsored by Withings, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06351761 being conducted?

This trial has 4 study locations across Florida, Val de Marne. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.